Evidence map›Paper›PMID 40048983›Full record

ArticleGynecologic oncology2025

All-cause mortality and neighborhood social vulnerability among women with ovarian cancer.

Austin Hicks, Lauren Borho, Esther Elishaev, Jessica Berger, Michelle Boisen, John Comerci, Madeleine Courtney-Brooks, Robert P Edwards, Alison Aunkst Garrett, Joseph L Kelley and 7 more

Abstract read
In one paragraph

Article in Gynecologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Austin HicksDepartment of Statistics, University of Pittsburgh College of Arts and Sciences, Pittsburgh, PA, United States of America.
Lauren BorhoDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America; Women's Cancer Research Center, Magee-Womens Research Institute and Foundation and Hillman Cancer Center, Pittsburgh, PA, United States of America.
Esther ElishaevDepartment of Pathology, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America; Women's Cancer Research Center, Magee-Womens Research Institute and Foundation and Hillman Cancer Center, Pittsburgh, PA, United States of America.
Jessica BergerDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America.
Michelle BoisenDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America.
John ComerciDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America.
Madeleine Courtney-BrooksDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America.
Robert P EdwardsDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America; Women's Cancer Research Center, Magee-Womens Research Institute and Foundation and Hillman Cancer Center, Pittsburgh, PA, United States of America.
Alison Aunkst GarrettDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America.
Joseph L KelleyDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America.
Jamie LesnockDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America.
Haider S MahdiDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America; Women's Cancer Research Center, Magee-Womens Research Institute and Foundation and Hillman Cancer Center, Pittsburgh, PA, United States of America.
Alexander OlawaiyeDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America; Women's Cancer Research Center, Magee-Womens Research Institute and Foundation and Hillman Cancer Center, Pittsburgh, PA, United States of America.
Shannon RushDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America.
Paniti SukumvanichDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America.
Sarah TaylorDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America; Women's Cancer Research Center, Magee-Womens Research Institute and Foundation and Hillman Cancer Center, Pittsburgh, PA, United States of America.
Francesmary ModugnoDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee-Womens Research Institute and Foundation, Pittsburgh, PA, United States of America; Women's Cancer Research Center, Magee-Womens Research Institute and Foundation and Hillman Cancer Center, Pittsburgh, PA, United States of America; Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA, United States of America; Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America. Electronic address: modugnof@upmc.edu.

Funding

Project 3: Hedgehog Inhibition to Enhance Response to ICI TherapyP50CA272218 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Alexander Olawaiye · 2023 to 2026
$11.0M
OVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERSK07CA080668 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MODUGNO, FRANCESMARY · 2000 to 2005
$661k
Multi-omic Predictive Markers for Ovarian Cancer Therapy Response and OutcomesR21CA267050 · NCI · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MODUGNO, FRANCESMARY · 2022 to 2023
$408k
Hormones, DNA Repair, BRCA1/2 and Ovarian Cancer Preven*R03CA092776 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MODUGNO, FRANCESMARY · 2002 to 2003
$149k
NCI NIH HHS K07 CA080668NCI NIH HHS P50 CA272218NCI NIH HHS R03 CA092776NCI NIH HHS R21 CA267050
6 · The paper itself

Abstract

objectiveNeighborhood-level social determinants of health (N-SDoH) impact cancer survival. However, the relationship between N-SDoH and epithelial ovarian cancer (EOC) survival remains understudied.

methodsWe used data on all Pennsylvania residents diagnosed with EOC from 2000 to 2023 throughout the University of Pittsburgh Medical Center to assess the impact of N-SDoH on survival. We used the Social Vulnerability Index (SVI) to characterize four N-SDoH themes and overall N-SDoH vulnerability based on each case's census tract at diagnosis. High-SVI overall and by N-SDoH theme was defined as being in the 75th percentile in Pennsylvania for that metric. Cox proportional hazard models assessed the association between high-SVI and overall mortality.

resultsAmong 4970 EOC cases, high-SVI overall was associated with later stage at diagnosis, greater residual disease, and a lower likelihood of receiving standard-of-care platinum-based therapy. High-SVI was also associated with a 13 % increased mortality hazard (adjusted-HR:1.13 95 %CI:1.02-1.25). The Household Characteristics, Racial and Ethnic Minority Status, and Housing Type and Transportation themes were also associated with increased mortality hazards (adjusted-HR[95 %CI]: 1.10[1.01-1.21], 1.23[1.08-1.39], 1.09[1.00-1.18], respectively). The Socioeconomic Status theme was associated with an increased mortality hazard of borderline significance (adjusted-HR 1.10, 95 %CI:0.99-1.23). The overall high-SVI association appeared similar when stratifying by race, although the number of Black cases was small (n = 168).

conclusionHigher neighborhood social vulnerability is associated with worse EOC survival. Replicating study findings in more diverse populations can help illuminate the neighborhood factors most influencing survival and support the design and testing of programs to reduce poor EOC outcome, especially within marginalized communities.

Indexed as

Carcinoma, Ovarian EpithelialNeighborhood CharacteristicsOvarian NeoplasmsSocial Determinants of HealthSocial VulnerabilityAdultAgedFemaleHumansMiddle AgedPennsylvaniaProportional Hazards ModelsResidence CharacteristicsCensus tractOvarian cancerSocial determinants of healthSocial vulnerability indexSurvival

Identifiers

PMID40048983
PMCPMC12210272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.